Premium
Innate Pharma SA (IPHA)
NASDAQ
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and periphe... Innate Pharma S.A. operates as a biotechnology company that develops immunotherapies for cancer patients in France and internationally. The company’s products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma; IPH4502, a novel and differentiated topoisomerase I inhibitor ADC conjugated to exatecan targeting Nectin-4; and Monalizumab, a dual checkpoint inhibitor that targets T Cells and NK Cells. It also develops IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway; IPH6401, an BCMA-targeting NK cell engager; IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. In addition, the company develops IPH6501, a tetra-specific NK cell engager to activate receptors, NKp46 and CD16, tumor antigen (CD20) and an interleukin-2 receptor. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech. Innate Pharma S.A. was incorporated in 1999 and is based in Marseille, France. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.01 | -0.558659217877 | 1.79 | 1.84 | 1.73 | 111488 | 1.76204409 | DR |
| 4 | -0.3 | -14.4230769231 | 2.08 | 2.2971 | 1.71 | 46138 | 1.79145691 | DR |
| 12 | 0.49 | 37.984496124 | 1.29 | 2.6199 | 1.21 | 78426 | 1.94819376 | DR |
| 26 | -0.06 | -3.26086956522 | 1.84 | 2.6199 | 1.17 | 48009 | 1.88505864 | DR |
| 52 | -0.11 | -5.82010582011 | 1.89 | 2.63 | 1.17 | 73723 | 2.12747071 | DR |
| 156 | -1.55 | -46.5465465465 | 3.33 | 3.5107 | 1.17 | 89966 | 2.31228723 | DR |
| 260 | -2.01 | -53.0343007916 | 3.79 | 11.95 | 1.17 | 184891 | 5.22788261 | DR |
Transactions différées
Pour obtenir des transactions en temps réel, améliorez votre compte
Passer à la version en temps réel| Aucune Discussion Trouvée |
| Ajouter une Discussion |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
